Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.

Matthias StelljesSimon RaffelNael AlakelRalph Wäsch Mustafa KondakciSebastian SchollAndreas RankMathias HänelBernd SpriewaldMaher HanounSonja MartinKatjana SchwabHubert ServeLena ReiserJulian KnadenHeike PfeiferJulia MarxTim SauerWolfgang E BerdelGeorg LenzMonika BrüggemannNicola GökbugetKlaus Wethmar

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

Inotuzumab ozogamicin-based induction followed by age-adapted chemotherapy was well tolerated and resulted in high rates of remission and OS. These data provide a rationale for integrating inotuzumab ozogamicin into first-line regimens for older patients with B-ALL.

Keyphrases

acute lymphoblastic leukemia
end stage renal disease
newly diagnosed
physical activity
ejection fraction
chronic kidney disease
community dwelling
middle aged
peritoneal dialysis
prognostic factors
gene expression
patient reported outcomes
patient reported
disease activity